Paper6961971
Uptake and metabolism of daunorubicin by human leukemia cells.
DeGregorio MW and 3 others. Cancer Chemother Pharmacol, 1982. Cited by 13 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Uptake and metabolism of daunorubicin by human leukemia cells. Papers, record 6961971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6961971
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Daunorubicin | Major topic |
| Leukemia | Major topic |
| Acute Disease | |
| Animals | |
| Biotransformation | |
| Cell Line | |
| Chromatography, High Pressure Liquid | |
| Humans | |
| Leukemia, Experimental | |
| Leukemia, Myeloid, Acute | |
| Time Factors |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 276,884 | Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. | Proc Natl Acad Sci U S A | 1978 | https://conductscience.org/library/papers/276884 | PubMed |
| 2 | 535,134 | Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/535134 | PubMed |
| 3 | 6,104,578 | Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. | Drug Metab Dispos | 1980 | https://conductscience.org/library/papers/6104578 | PubMed |
| 4 | 1,069,608 | Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. | Cancer Treat Rep | 1976 | https://conductscience.org/library/papers/1069608 | PubMed |
| 5 | 4,179,068 | Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. | Scand J Clin Lab Invest Suppl | 1968 | https://conductscience.org/library/papers/4179068 | PubMed |
| 6 | 7,428,784 | Comparative uptake, metabolism and retention of anthracyclines by tumors growing in vitro and in vivo. | Eur J Cancer (1965) | 1980 | https://conductscience.org/library/papers/7428784 | PubMed |
| 7 | 498,420 | Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/498420 | PubMed |
| 8 | 648,557 | Uptake and subcellular localization of daunorubicin and adriamycin in cultured fibroblasts. | Eur J Cancer (1965) | 1978 | https://conductscience.org/library/papers/648557 | PubMed |
| 9 | 398,688 | Daunorubicin reductase activity in leukemia leukocyte homogenates. | Arch Immunol Ther Exp (Warsz) | 1979 | https://conductscience.org/library/papers/398688 | PubMed |
| 10 | 6,945,901 | An in vitro model for acute myelogenous leukemia chemotherapy. | Cancer | 1981 | https://conductscience.org/library/papers/6945901 | PubMed |
| 11 | 7,053,847 | Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin. | Cancer Res | 1982 | https://conductscience.org/library/papers/7053847 | PubMed |
| 12 | 6,941,824 | Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells. | Blut | 1981 | https://conductscience.org/library/papers/6941824 | PubMed |
| 13 | 1,271,407 | Cellular pharmocodynamics of several anthrocycline antibiotics. | J Med Chem | 1976 | https://conductscience.org/library/papers/1271407 | PubMed |
| 14 | 7,266,019 | Differences in uptake of adriamycin and daunomycin by normal BM cells and acute leukemia cell determined by flow cytometry. | Leuk Res | 1981 | https://conductscience.org/library/papers/7266019 | PubMed |
| 15 | 4,264,560 | High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity. | Cancer | 1972 | https://conductscience.org/library/papers/4264560 | PubMed |
| 16 | 7,397,945 | Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/7397945 | PubMed |
| 17 | 6,930,988 | Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia. | Cancer Lett | 1980 | https://conductscience.org/library/papers/6930988 | PubMed |
| 18 | 977,683 | Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography. | J Chromatogr | 1976 | https://conductscience.org/library/papers/977683 | PubMed |
| 19 | 271,272 | Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. | Nature | 1977 | https://conductscience.org/library/papers/271272 | PubMed |
| 20 | 1,069,571 | Acute granulocytic leukemia: treatment of the disease. | Arch Intern Med | 1976 | https://conductscience.org/library/papers/1069571 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 8,431,976 | Targeting chemosensitizing doses of toremifene based on protein binding. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8431976 | PubMed |
| 6,690,077 | Uptake, metabolism, and cytotoxicity of doxorubicin in human Ewing's sarcoma and rhabdomyosarcoma cells. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6690077 | PubMed |
| 6,488,444 | Kinetics and sensitivity of daunorubicin in patients with acute leukemia. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6488444 | PubMed |
| 3,891,121 | Uptake and metabolism of daunorubicin by human myelocytic cells. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/3891121 | PubMed |
| 1,463,871 | Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells. | Breast Cancer Res Treat | 1992 | https://conductscience.org/library/papers/1463871 | PubMed |
| 1,386,843 | Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells. | Invest New Drugs | 1992 | https://conductscience.org/library/papers/1386843 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6961971
GET https://conductscience.org/api/papers/v1/6961971/references?page=2